EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC-ND 4.0

Diagnostic performance of SHOX2 and RASSF1A gene methylation assays in malignant pleural effusion: A systematic review and meta‐analysis

Mohamed Smail Aissani, Kyrillos Mahrous Gerges iD, Ahmed Msherghi, Hajer Farrara, Dawood Alatefi, Imane Chenfouh iD, Arwi Omar Kara, Maram Abuajamieh, Ghada Kareem, Mohammed Benhammou, Mohamed E Ali, Max Wintermark und 1 weitere

Cancer Cytopathology · 2025

DOI: 10.1002/cncy.70031 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancer Cytopathology, 2025. Verfasst von Mohamed Smail Aissani und 12 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University Blida 01, Blida, Algeria. Hauptthemen laut MEDLINE: Tumor Suppressor Proteins, DNA Methylation, Homeodomain Proteins, Pleural Effusion, Malignant. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Malignant pleural effusion (MPE) is a common complication of advanced malignancies, requiring differentiation from benign pleural effusion for appropriate management. Cytology and biopsy have limitations, necessitating more sensitive, less invasive diagnostic techniques. The objective of this study was to evaluate the diagnostic accuracy of methylated SHOX2 (short‐stature homeobox 2) and RASSF1A (Ras association domain family member 1A) genes in detecting MPE.

Methods

A systematic review and meta‐analysis included studies that compared benign pleural effusion and MPE cohorts using methylation of SHOX2 and RASSF1A genes in pleural fluid as the index test and cytology/histopathology as the reference standard. A random‐effects model was used to calculate sensitivity, specificity, predictive values, and diagnostic odds ratios. Subgroup analysis assessed performance in lung‐predominant versus nonlung‐predominant MPE.

Results

Four studies with a total of 534 participants were included. The pooled sensitivity and specificity were 85% (95% confidence interval [CI], 53%–96%; heterogeneity [I 2 ] = 0.00%) and 92% (95% CI, 88%–95%; I 2 = 24.8%), respectively. The positive and negative predictive values were 93% (95% CI, 85%–97%; I 2 = 61.5%) and 84% (95% CI, 53%–96%; I 2 = 0.00%), respectively. The diagnostic odds ratio was 22.78 (95% CI, 11.00–47.17; I 2 = 25.8%). Subgroup analysis showed a slight decrease in sensitivity (70%; 95% CI, 64%–76%; I 2 = 0.00%) and specificity (91%; 95% CI, 86%–94%; I 2 = 26.1%) when excluding the study with a lung cancer‐predominant population.

Conclusions

The combined analysis of SHOX2 and RASSF1A methylation demonstrated promising diagnostic accuracy for MPE detection, outperforming cytology. This less invasive method could reduce reliance on more invasive procedures, although further research is needed to confirm its efficacy across diverse populations and cancer types.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Suppressor ProteinsDNA MethylationHomeodomain ProteinsPleural Effusion, MalignantBiomarkers, TumorHumansSensitivity and Specificity

Stichwörter der Autor:innen

Ras association domain family member 1A (RASSF1A)diagnostic accuracymalignant pleural effusionmethylation biomarkersshort‐stature homeobox 2 (SHOX2)

Substanzen

SHOX2 protein, humanTumor Suppressor ProteinsRASSF1 protein, humanHomeodomain ProteinsBiomarkers, Tumor

Autor:innen und Institutionen

  • Faculty of Medicine, University Blida 01, Blida, Algeria.
  • Ibrahime Tirichine Public Hospital, Blida, Algeria.
  • Faculty of Medicine, Sohag University, Sohag, Egypt.
  • The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Graduate School of Public Health and Health Policy, City University of New York, New York, New York, USA.
  • University of Jordan, Amman, Jordan.

ORCID-Profile: Kyrillos Mahrous Gerges, Imane Chenfouh, Muhammed Elhadi

Zitieren

APA

Aissani, M. S., Gerges, K. M., Msherghi, A., Farrara, H., Alatefi, D., Chenfouh, I., Kara, A. O., Abuajamieh, M., Kareem, G., Benhammou, M., Ali, M. E., Wintermark, M., & Elhadi, M. (2025). Diagnostic performance of SHOX2 and RASSF1A gene methylation assays in malignant pleural effusion: A systematic review and meta‐analysis. Cancer Cytopathology. https://doi.org/10.1002/cncy.70031

Vancouver

Aissani MS, Gerges KM, Msherghi A, Farrara H, Alatefi D, Chenfouh I, et al. Diagnostic performance of SHOX2 and RASSF1A gene methylation assays in malignant pleural effusion: A systematic review and meta‐analysis. Cancer Cytopathology. 2025. doi:10.1002/cncy.70031

BibTeX
@article{Aissani2025,
  author = {Aissani, Mohamed Smail and Gerges, Kyrillos Mahrous and Msherghi, Ahmed and Farrara, Hajer and Alatefi, Dawood and Chenfouh, Imane and Kara, Arwi Omar and Abuajamieh, Maram and Kareem, Ghada and Benhammou, Mohammed and Ali, Mohamed E and Wintermark, Max and Elhadi, Muhammed},
  title = {Diagnostic performance of SHOX2 and RASSF1A gene methylation assays in malignant pleural effusion: A systematic review and meta‐analysis},
  journal = {Cancer Cytopathology},
  year = {2025},
  doi = {10.1002/cncy.70031}
}
Kostenlos starten →